PDCD1 and skin squamous cell carcinoma: Given the notable, albeit limited, success of PD-1-targeted immunotherapy in the treatment of established/advanced cSCC, future research in this context is likely to involve assessment of the immunotherapeutic efficacy of the dual administration of inhibitory ICM-targeted mAbs with novel intra-lesional agents such as STP705.